Tarsus Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition brings a late-stage ocular antiseptic asset with strong clinical differentiation and a clear regulatory path, targeting a large unmet need in retinal procedures. The deal leverages existing commercial strengths, offers significant market potential, and preserves financial flexibility.
-
XDEMVY has achieved rapid adoption and strong revenue growth, with peak sales guidance raised to over $2 billion due to expanded prescriber base and effective DTC campaigns. The company is advancing its pipeline in ocular rosacea and Lyme disease, while maintaining a robust commercial infrastructure and monitoring profitability opportunities.
-
XDEMVY continues strong commercial growth with expanded DTC campaigns and robust reimbursement, while new key account leaders and clinical studies drive deeper market penetration. Pipeline programs for ocular rosacea and Lyme disease are advancing, with pivotal data expected in 2027.
-
XDEMVY has achieved strong adoption with over 20,000 prescribers and 500,000 patients treated, driving a raised peak sales outlook to $2 billion. Pipeline programs in ocular rosacea and Lyme disease prevention are advancing, with robust reimbursement and a solid cash position supporting continued growth.
-
XDEMVY has driven strong revenue growth and broad prescriber adoption, supported by effective DTC campaigns and a robust sales strategy. Pipeline programs in ocular rosacea and Lyme disease offer significant future potential, while international expansion is being evaluated amid policy considerations.
-
XDEMVY’s commercial momentum continues with strong Q1 results, expanding prescriber base, and improved DTC ROI. Pipeline assets in ocular rosacea and Lyme disease advance, with strategic focus on operating leverage and payer value. Guidance and market opportunity remain robust.
-
Q1 2026 saw XDEMVY net product sales rise over 85% year-over-year to $145 million, with strong physician adoption and expanding retreatment rates. Full-year guidance of $670–$700 million in sales was reaffirmed, and pipeline programs for Lyme disease and ocular rosacea advanced on schedule.
-
XDEMVY's launch has exceeded expectations, with rapid revenue growth, broad payer coverage, and strong prescriber engagement. The addressable market remains largely untapped, and DTC campaigns are expanding awareness. Peak sales guidance has doubled to $2B+, with a robust pipeline and strong financials supporting future growth.
-
The company is rapidly expanding in eye care, with XDEMVY achieving $450M in revenue and targeting $2B+ peak sales. Pipeline assets TP-04 and TP-05 address large unmet needs, with key data expected in 2027. Strategic investments in DTC and sales force expansion support continued growth.
Fiscal Year 2025
-
Full-year 2025 net sales reached $451.4 million, with XDEMVY now profitable and US peak sales potential raised to over $2 billion. 2026 guidance projects 50%+ revenue growth, strong gross margins, and continued pipeline expansion, supported by robust prescriber and patient demand.
-
Strong Q3 results and robust revenue guidance reflect effective commercial execution and DTC strategy. Pipeline progress includes a phase II ocular rosacea study starting by year-end and a Lyme disease prophylactic advancing toward partnership.
-
Q3 2025 saw exceptional growth, with XDEMVY achieving $119M in net sales and over 103,000 bottles dispensed, driven by strong physician adoption and DTC efforts. Guidance for Q4 and 2025 remains robust, with continued expansion in pipeline and international markets.
-
XDEMVY continues robust growth with strong prescriber engagement, high insurance coverage, and effective DTC campaigns. Expansion efforts focus on increasing prescribing depth, retreatment rates, and international markets, while pipeline assets in ocular rosacea and Lyme disease prevention advance toward clinical milestones.
-
Record Q2 net sales of $102.7M and 91,000 bottles dispensed highlight XDEMVY's rapid adoption, driven by DTC campaigns and broad access. Guidance calls for continued growth, with a robust pipeline and expanding prescriber base supporting long-term potential.
-
XDEMVY's launch has driven strong sequential growth, aided by an expanded sales force and early payer coverage. Prescribing is broadening across multiple eye care categories, with significant market potential remaining. Pipeline programs in ocular rosacea and Lyme disease are advancing, and international expansion is underway.
-
XDEMVY continues to drive strong revenue growth, with expanding adoption among eye care professionals and a robust sales force. Pipeline programs in ocular rosacea and Lyme disease offer significant future opportunities, while international expansion and business development are underway.
-
XDEMVY's launch has exceeded expectations, driven by strong prescriber education, broad payer coverage, and expanding sales force efficiency. Growth is supported by direct-to-consumer campaigns and new market opportunities, with a robust pipeline targeting ocular rosacea and Lyme disease.
-
XDEMVY’s launch has driven strong demand, broad payer coverage, and rapid physician adoption, with a focus on expanding within a 9 million patient segment and deepening engagement among 15,000 key prescribers. Pipeline assets target ocular rosacea and Lyme disease, supported by robust financial resources.
-
XDEMVY's launch has exceeded expectations, with strong sales, broad payer coverage, and ongoing market education driving growth. International expansion and a robust pipeline targeting ocular rosacea and Lyme disease are underway, supported by a strong cash position.
-
XDEMVY's launch has surpassed expectations, with strong revenue growth, broadening prescriber adoption, and over 90% payer coverage. Pipeline development continues with ocular rosacea and Lyme disease programs, while DTC and Salesforce expansion are set to drive further growth.
-
Q1 2025 delivered $78M in XDEMVY sales, up 217% year-over-year, driven by expanded coverage, increased prescribing frequency, and robust DTC campaigns. The company raised $135M in equity, maintains strong gross margins, and expects continued growth with new pipeline advances and increased marketing investment.
-
XDEMVY achieved strong initial sales and broad coverage, with significant market potential remaining. The company is advancing a gel-based ocular rosacea program and an oral Lyme disease prophylactic, while focusing on execution and measured business development.
-
The company is driving strong adoption of its FDA-approved therapy for Demodex blepharitis, achieving broad market coverage and robust sales growth. Strategic expansion includes a new gel for ocular rosacea, with a phase II trial starting in H2 2024, and ongoing efforts to deepen physician and patient engagement.
-
Xdemvy's strong launch drove significant revenue, with broad physician adoption and a focus on expanding indications such as ocular rosacea. Growth in 2025 will be supported by new sales reps, DTC campaigns, and improved Medicare coverage, while seasonality and gross-to-net dynamics will impact quarterly results.
-
Strong growth is projected for Xdemvy in 2025, supported by broad coverage, direct-to-consumer campaigns, and a motivated sales force. Expansion into ocular rosacea represents a major new opportunity, with Phase 2 trials planned and a proven commercialization blueprint in place.
Fiscal Year 2024
-
2024 saw record Xdemvy sales, broad insurance coverage, and a major DTC campaign launch, driving strong physician and patient engagement. The pipeline advanced with new programs in ocular rosacea and Lyme disease, both with clear regulatory paths and upcoming trials.
-
Record Q3 sales and expanded coverage drove strong growth, with XDEMVY adoption deepening among ECPs and new data supporting broader use in MGD patients. Guidance calls for continued sales momentum and robust financial health, with no further sales force expansion needed for near-term growth.
-
Strong launch momentum with nearly 100,000 patients treated and $40M in Q2 revenue, supported by expanding coverage and a growing sales force. Direct-to-consumer campaigns and pipeline updates in MGD and Lyme disease are set to drive further growth into 2025.
-
XDEMVY's launch shows strong adoption by payers and physicians, aided by sales force growth and an upcoming DTC campaign. The large addressable market has peak sales potential over $1 billion. Gross-to-net discounts are improving, with updates on development programs and financial guidance expected by year-end.
-
Q2 2024 saw $40.8M in sales, a 65% sequential increase, with XDEMVY adoption by 11,000 ECPs and improved gross-to-net discount to 44%. Growth is expected to accelerate in Q4 with a fully expanded sales force and DTC campaign, while retreatment volumes are projected to rise in 2025.
-
Xdemvy’s launch for Demodex blepharitis has exceeded expectations, with strong prescriber uptake, robust payer coverage, and expanding patient engagement. Growth is driven by new patient starts, with retreatments expected annually. Pipeline and international expansion offer additional upside.
-
Product sales and prescriber adoption are growing rapidly, supported by a strong balance sheet and expanding sales force. Full commercial and Medicare coverage is expected by 2025, with DTC advertising planned to further expand the market. Pipeline programs offer additional growth opportunities.
-
Xdemvy's launch for Demodex blepharitis has been highly successful, with strong sales, positive real-world efficacy, and expanding physician adoption. The company is investing in sales force growth, direct-to-consumer marketing, and advancing a robust pipeline, all supported by a strong financial position.